In chronic renal failure patients an increase in heparin dose during haemodialysis is frequently required during the course of therapy with NeoRecormon as a result of the increased packed cell volume.
Hemodialüüsi ajal tuleb NeoRecormon- ravi saavatel kroonilise neerupuudulikkusega patsientidel sageli hepariini annuseid suurendada seoses hematokriti tõusuga.